Heghine Khachatryan: Real-World Data on DOAC Use in Pediatric Oncology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared RPTH’s post on LinkedIn:
“New evidence continues to refine our understanding of anticoagulation in complex pediatric populations.
A recent publication in Research and Practice in Thrombosis and Haemostasis (RPTH) explores the safety and efficacy of direct oral anticoagulants (DOACs) in pediatric oncology patients, presenting real-world data from two tertiary pediatric centers.
Children with cancer represent a particularly vulnerable group, where thrombosis risk is increased due to malignancy, central venous catheters, and treatment-related factors.
Determining the optimal balance between thrombosis prevention and bleeding risk remains a critical clinical challenge.
Real-world data such as these are essential for guiding evidence-based decisions and improving outcomes in pediatric cancer-associated thrombosis.
Continued research will help clarify the role of DOACs in this delicate patient population.”
RPTH Journal shared a post on LinkedIn about a recent article by Riten Kumar et al, adding:
“Are DOACs truly safe for children with cancer-associated thrombosis?
Direct oral anticoagulants are transforming anticoagulation in adults.
But in pediatric oncology, the evidence base is still evolving.
A new real-world RPTH study examined 51 children with cancer receiving DOACs for treatment or prevention of VTE across two major pediatric centers.
Here’s the key signal:
- Recurrent or progressive thrombosis occurred in 8% of patients
- Major bleeding occurred in 6%, and clinically relevant nonmajor bleeding in 20%.
What’s important about these findings
- Most patients received rivaroxaban or apixaban
- Nearly half achieved complete thrombus resolution on follow-up imaging
- Bleeding events were often linked to chemotherapy-related thrombocytopenia
- Real-world complication rates were higher than some clinical trials
Translation:
DOACs are promising in pediatric oncology but real-world complexity matters.
Big questions moving forward:
- What is the optimal anticoagulation intensity in children with cancer?
- How should platelet thresholds guide anticoagulation decisions?
- Can we better balance thrombosis prevention with bleeding risk during chemotherapy?”
Title: Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers
Authors: Riten Kumar, Emily Drake, Joseph Stanek, Nicholas Yeager, Lynda M. Vrooman, Lewis B. Silverman, Vilmarie Rodriguez
Read the Full Article on RPTH
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Apr 22, 2026, 17:19Ralf Ludwig: Bridging Population Data and Immunology in Inflammatory Diseases
-
Apr 22, 2026, 17:15Giacomo Rossi: Genetic Study Reveals 10 Genes in Hyperemesis Gravidarum
-
Apr 22, 2026, 17:06Maura Boerio: Quantifying Barriers to Care in Vascular Ehlers-Danlos Syndrome
-
Apr 22, 2026, 17:05Kausik Ray։ Metabolically Healthy Obesity Is Being Re-Evaluated as a High-Risk Condition Needing Closer Attention
-
Apr 22, 2026, 16:58Baba-Jallah Epega: Sickle Cell Resilience Through Patient Voices and Clinical Insight
-
Apr 22, 2026, 16:44Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
-
Apr 22, 2026, 16:29CBTH 2026 Opens with First Workshop in Germany – European Hematology Association
-
Apr 22, 2026, 16:16Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL